The relevance of the creation of antihistamine medicines for external use

Herasymova Iryna, Yarnykh Tetyana, Akopyan Alina

Department of Drugs Technology

National University of Pharmacy of Ministry of Health of Ukraine,

Kharkiv, Ukraine

iryna_herasymova@ukr.net

The creation of highly effective antihistamine drugs is one of the most important tasks of medical and pharmaceutical science. Modern approaches to the treatment of allergic dermatoses involve the use of soft dosage forms, mainly glucocorticosteroids, which have rather serious side effects and require constant medical supervision.

Naturally, the need arose to obtain such antihistamines that, firstly, would have a high affinity for H1 receptors, providing strong binding to receptors and a long-term therapeutic effect; secondly, they would have a high selective blockade of H1 receptors without affecting the receptors of other physiological mediators, which would allow one to get rid of the side effects of H1 antagonists of the 1st and 2nd generation: actions on the cardiovascular system, vision, gastrointestinal intestinal tract and central nervous system. These severe complications prompted research to radically improve the profile of antihistamines. The drug of the 3rd generation with antihistamine action is fexofenadine, registered in the Ukraine and others countries under the trade names Telfast, Fexofast, Alexofast, Allegra, Altiva, Fexomax etc.

Fexofenadine is a 3-generation antihistamine with powerful anti-allergic activity and additional anti-inflammatory, anti-edema and antipruritic effects. Currently, this drug is presented on the pharmaceutical market only in solid dosage forms. The good tolerance of fexofenadine makes it possible to recommend it for the treatment of a wide range of allergic diseases and reactions in the practice of dermatologists, allergists and other specialists, optimizing the treatment of dermatological patients.

The use of fexofenadine in medical practice has confirmed its safety profile, high therapeutic efficacy, the ability to significantly improve the quality of life of patients, but also has additional antiallergic properties. External dosage forms with antiallergic antihistamines are currently limited to two substances belonging to the first and second generation antihistamines.

Considering the small share of currently existing external dosage forms on the Ukrainian pharmaceutical market, as well as the absence of a soft dosage form of fexofenadine, the development of a new dermatological form with fexofenadine will expand both its pharmacological spectrum and the range of antihistamine ointments, which is undoubtedly an urgent task in the development of modern pharmaceutical market.